Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies.

NE, Breslow; SS, Ou; JB, Beckwith; GM, Haase; JA, Kalapurakal; ML, Ritchey; RC, Shamberger; PR, Thomas; GJ, D'Angio; DM, Green

doi:10.1002/cncr.20433

Public

Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies.

Published in Cancer • Sep 1, 2004

Authors:

Breslow NE

Ou SS

Beckwith JB

Abstract

<h4>Background</h4>After randomized trials in the 1980s, doxorubicin (DOX) was added to dactinomycin plus vincristine as standard chemotherapy for patients who had Stage III Wilms tumor (WT) of favorable histology (FH). Double-agent chemotherapy was retained for patients with Stage II disease. In th...

View

Paywalled

View Full Text

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Generate AI Take for this paper

Discussions